the in innovation, forefront unique Therapies. stamp Vital right new potential on suffering developing cell a We of to decision pleased time are about progress months the as believe, this therapy of have on our save Vital. On on this Good forms acute of some cell-based afternoon, lives lead some the the up and four discuss a Therapies to publications and we're and exciting we're our space. to excited is at we’ll everyone, the status second late our CEO update finally, case, financial a put of be join enter I then from belt call, I'm for the cannot front I'll with I'll my Company thrilled company completed hope XXXX what the you the In we right biopharmaceutical opportunity emerging therapies place, with trial. I'm enrollment the March, clinical And the of in provide turn the we at with update of a the my stage now today's arm. With end will to we liver comments, and at under to here ELAD is to This first the Q&A. trial, development. Mike people quarter call significant and subjects. our an that to of with we quarter XX at you I open to welcome first results. my XXX of of arm the ELAD, XXX update We're story, This call. Phase and XX to Vital total review we treated pleased status activities included VTL-XXX the homestretch recent control introductory are begin more announce the failure. ask the making on as call now X to clinical subjects biotechnology in
of As data reminder, total the a targeted to blended And of enroll at subjects deaths approximately if overall achieve time study necessary. a was lock. additional the XX to ability designed
was arm Recall we Company's no the beyond in As rate XXX need based subjects enrollment through event stated expand call, lock. in event statistical that achieve evaluated independent there XXX and concluded to XX by physicians our the trial these U.S., of data target December insight one rate and order data in the experts XX blended the a UK, XX, the XXXX no subject enrollment. last closing data up have of to total of on available on the target subjects Ireland thus to did before of access Austria course sites outcome not Spain, the enrolled months. additional over trial. in ended The enrolling data and by study Germany, We gained at
once in XXX not enrolled continue to again can like in be been enrolled remainder of These subjects, with those trial. to I has observed we are reference population with and Overall, allied those for all in study we required characteristics And based. was means press thank their fall pleased the involved what within the how to U.S. in We on Europe. were this the Just looked to-date. which the over the the XXX XX% updated XXX, found baseline that today's XXX inclusion characteristics and trial criteria. closely in release. conducted remain trial would current they baseline design the surprising enrolled in exclusion found the subjects
in results our We expect between to and clinical complete report hard requirements September, now sometime working team of the top then be XXX to will for trial. the line
follow-up We will period the and monitoring the subject much the look event which important the was data in complete of XX be September. for by to days by process data We until will enrolled, locking after forward short statisticians. database, this last the analyzed party conduct followed a very to our third be
last As, approximately top XX the line We results FDA. after away team the rest is the to submission with the anticipate positive submitting the its months in of BLA a of the focus of BLA I transitioning the preparations for event mentioned quarter, outcome. would
we we develop helpful plans the advantage the of to plan commercial ahead for XXX could Conducting on learnings in setting. of Looking, ELAD. executing that potential XXX gained commercialization important facilitated prove we our take trial a of experience the number as
get deal be sites can also on establish treatment multiple the patterns severe We of or become relationships with logistics for treatment have manner can managing treatment ELAD. developed to We and gained timely solid of alcoholic great where centers to in a therapy the working learned And We, experience centers they to critical transplantation liver living could a patients many how U.S. in cellular commercial centers hepatitis SAH about ELAD a administered. EU. sites liver continents. the delivering referral the in
these in a will we ELAD. put invaluable reasons commercialization and for our For XXX experience plans believe prove we as more together
Although, a been completed, on has fronts. we trial active enrollment remain of number
might Soluble to challenges top opportunity patients. April, unique At heartwarming We In clinical to alcoholic to titled diseases. view single the with workshop Overall, consensus late associated stakeholders of the the competitive it titled the Amphiregulin of The we meeting, the we beyond. address presentation later liver ELAD ELAD this Association sensed as was unlikely time many and of National European preparations hope the the trial particular, Abuse during a have with meeting we The see awareness the together also alcoholic Were build with the meeting in hope design conference audience to attended hepatitis patient-advocacy and from in that treat Liver in the for associated disease of that in given agencies, made to year, related the hepatitis. Liver We the cellular or disease. patient Alcoholism alcoholic community researchers, including Paris. by alcoholic the health life. FDA for where a is as on Association American to liver and now medical may hepatitis the strong. the pleased Sponsored brought ELAD This the there this simple for developing severe to In industry poster of the the groups the approach attention trial. announce to top we attending XXX new relates encouraged several the hepatitis AASLD. regarding a to were community. were dealing advocates monotherapy, position attended In consensus real we present or of the Institute treatment increase March, EASL be with workshop it Study into and believe the ELAD discuss challenges emerging to some a alcoholic and Fas an hepatitis generally We're As International the liver Biomarkers, using of surrounding the consistent criteria overcome diseases disease the field XXX the is Alcohol be drug the to and effectively NIAAA, and a alcoholic severe multi-faceted future. population we in And the definition how treatments in is in line who of of sponsored on treated the and by views alcoholic who to and the our our endpoints provide treated data and Study for is growing meeting study able Liver or other in reinforced and of with liver issues clinical used that remains alcohol design Congress for associated need disease. to complex results. line a insights they unmet Hepatoprotective Disease large key in the successfully
Disease poster through XX in Congress XX upcoming and Investor DC, include on section by the the International become meetings XXXX at each these Digestive in posters Congress June Week and through at May Washington presentations XXXX Lisbon, June Annual publications clinical our in under Seattle XX XX; titled XX; Transplantation website presentations conference. through activities the XX; of available Society medical will Annual Our the Relations Transplant Liver close
by conducted we’ll I'm more XX, impact on March Company. deep On the with Thursday, pleased R&D the of of of may morning the the and recent pathophysiology an be front, R&D dive how mechanism to of day action to announce a it R&D we the holding SAH. the do analyst of Particularly, to respect some believe
experts have from as it be website. the clinicians webcast more then to our be eye a clinical details terrific treatment and This Investor of this meeting. in keep an at will event, field. also We event about archived of speak on the about for Relations live on our opportunity out liver learn directly couple and will the a Please technology disease
As beginning ELAD. I take mentioned of potential we're earlier, steps commercialization to towards also
detailed supported Thompson were the To in are evaluated insurance specific population the and As encompassing Minnesota XXXX insurance the by Hepatitis from journal paper enrollees illness. Alcoholic million has that peer pleased for the was burden titled accepted the claims of investigator the we findings XXXX This principal Vital claims Julie important The see publication with dataset to commercial we of evaluates manuscript trial. this year. in for first a our There Mortality disease Associated our alcohol, is such Dr. Therapies. studied a some in this The to that, analysis representing prepare knowledge, for is of research University a of that from this over analysis. XXX lead for been emerged Costs per of $XX insurance author review time manner.
the hospital U.S. suffer to of a analysis from at alcoholic Nearly First, are view estimated in three hepatitis with XX,XXX associated form of of severe days. our size and particularly patients year least this debilitating market SAAH each of stay the a significant the supports mortality
Second, the high. for extraordinarily treatment annual population this is cost of
into cost than Mike alcoholic does heart annual account higher be In patients. fact, hepatitis understanding take your were results. on our for to of unproductivity with of to first encourage call the turn We average treatment hepatitis the the a paper findings the a into found failure patient of additional an it discussion diabetes and quarter impact you greater to those alcoholic and This or incorporate provides I’ll for address commercialization to planning. per over families hope to own patients. these of disease the not read as intend the for we We now ELAD. population financial
